Group 1 - The core viewpoint of the news is that Junshi Biosciences has shown significant trading activity, with a notable increase in stock price and substantial financing and margin trading data indicating a high level of investor interest [1][2] Group 2 - On January 9, Junshi Biosciences' stock price increased by 4.09%, with a trading volume of 520 million yuan [1] - The financing buy-in amount for Junshi Biosciences on the same day was 47.67 million yuan, while the financing repayment was 55.29 million yuan, resulting in a net financing outflow of 7.62 million yuan [1] - As of January 9, the total financing and margin trading balance for Junshi Biosciences was 1.344 billion yuan, with the financing balance accounting for 4.42% of the circulating market value, indicating a high level compared to the past year [1] - In terms of margin trading, on January 9, Junshi Biosciences had a margin repayment of 5,125 shares and a margin sell-out of 3,000 shares, with the sell-out amount calculated at 117,600 yuan [1] - The margin balance was 15.43 million yuan, exceeding the 90th percentile level over the past year, indicating a high level of short selling activity [1] Group 3 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] - As of September 30, the number of shareholders for Junshi Biosciences was 35,900, an increase of 15.17% from the previous period, while the average circulating shares per person decreased by 12.96% [2] - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year increase of 35.72% [2] - Among the top ten circulating shareholders, E Fund's Science and Technology Innovation Board 50 ETF held 19.39 million shares, a decrease of 2.82 million shares from the previous period [2] - Another major shareholder, Huaxia's Science and Technology Innovation Board 50 Component ETF, held 18.97 million shares, down by 1.07 million shares from the previous period [2]

Core Viewpoint - Junshi Biosciences (688180.SH) is currently trading at 38.69 yuan, reflecting a decline of 1.30% and is in a state of share price decline since its IPO [1] Fundraising and Financial Performance - Junshi Biosciences was listed on the Shanghai Stock Exchange's STAR Market on July 15, 2020, with an initial issuance of 87.13 million shares at a price of 55.50 yuan per share, raising a total of 4.836 billion yuan, netting 4.497 billion yuan after expenses [2][3] - The company planned to raise 2.7 billion yuan for innovative drug research, industrialization projects, loan repayment, and working capital [2] - The total fundraising from two rounds amounts to 8.612 billion yuan [4] - In the years from 2016 to 2024, the net profit attributable to shareholders has shown consistent losses, with figures of -1.35 billion, -3.17 billion, -7.23 billion, -7.47 billion, -16.69 billion, -7.21 billion, -23.88 billion, -22.83 billion, and -12.81 billion yuan respectively [4] - For the first three quarters of 2025, the company reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, but still recorded a net loss of 0.596 billion yuan, an improvement from the previous year's loss of 0.927 billion yuan [4]

Economic Overview - The US unemployment rate has decreased to 4.4%, while non-farm payrolls added only 50,000 jobs in December, indicating a cautious hiring environment [9][12] - Consumer confidence in the US has risen to a four-month high, with the Michigan University consumer sentiment index at 54, up from 52.9 in December [12][16] - In Iran, widespread protests challenge the theocratic regime, marking the most severe test since the 1979 Islamic Revolution [9][12] Market Performance - The Shanghai Composite Index rose by 0.92% to 4120.43 points, marking a continuous upward trend with 16 consecutive days of gains [1][6] - The Hang Seng Index increased by 0.32% to 26231.79 points, with significant gains in the gold and internet healthcare sectors [1][6] - Major US indices also saw gains, with the Dow Jones up 0.48% to 49504.07 points, and the S&P 500 rising by 0.65% to 6966.28 points [1][6] Industry Insights - China's top antitrust authority has initiated an investigation into the competitive landscape of the food delivery platform industry, citing concerns over subsidy-driven price wars that are squeezing the real economy [9][12] - Major platforms like Alibaba, Meituan, and JD.com have committed to cooperating with the investigation [12] - The investigation aims to promote lawful and fair competition within the market, addressing the issue of "involution" in the industry [12]

Core Viewpoint - The "2026 Medical and Health Sustainable Innovation Case Recommendation List" aims to promote sustainable development in the healthcare industry through the integration of artificial intelligence and healthcare, with a focus on technological innovation [1]. Group 1: Categories of Case Collection - The case collection includes four categories: 1. **International Innovation Localization**: Focuses on local production of innovative products, investment in local enterprises, and localization of marketing and services [2]. 2. **Local Innovation Globalization**: Emphasizes product innovation and quality assurance, establishing localized networks overseas, and enhancing brand visibility in international markets [2]. 3. **ESG Innovation Practice**: Involves sustainable market strategies, community services, and a sustainable supply chain [2]. 4. **Healthcare + AI Innovation**: Aims to address industry pain points, improve diagnostic efficiency, and ensure data security while promoting healthcare accessibility [2]. Group 2: Evaluation Committee - The evaluation committee consists of 20 senior professionals from both domestic and foreign healthcare sectors, including executives, policymakers, and experts from investment institutions [4]. Group 3: Timeline for Case Collection and Evaluation - The timeline for the case collection and evaluation process is as follows: - **January to March 2026**: Case collection through self-nomination or committee nomination [9]. - **April to May 2026**: Initial screening and online interviews with shortlisted companies [9]. - **June 2026**: Comprehensive evaluation by the nomination committee [9]. - **July 2026**: Official release of the list at the "AI + Healthcare Industry Sustainable Innovation Forum" during the Shanghai World Artificial Intelligence Conference [9].

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of January 11, 2026 [3] Core Insights - 2025 marked a significant year for Chinese innovative drugs going overseas, with total transaction amounts reaching $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs [4] - The innovative drug index saw a 35.31% increase in 2025, outperforming the CSI 300 index by 17.65% [4] - The trend of Chinese innovative drugs going global is expected to strengthen in 2026, with significant deals such as the one between Yilian Biotech and Roche for the YL201 project, which includes a $570 million upfront payment [4] - The small nucleic acid drug sector is experiencing breakthroughs, with GSK's Bepirovirsen showing positive results in Phase III trials for chronic hepatitis B, potentially becoming the first drug to achieve functional cure [5] - The report highlights the importance of oral autoimmune drugs, with Takeda's TYK2 inhibitor showing promising results in treating moderate to severe plaque psoriasis [6] - The brain-computer interface technology is entering a critical industrialization phase, with companies like Neuralink set to produce devices in 2026, supported by favorable policies and clinical trials in China [8] - The ZAP-X radiotherapy device is expected to capture a significant market opportunity in China, with the non-invasive tumor radiotherapy market projected to grow from RMB 27.2 billion in 2018 to RMB 59.4 billion by 2024 [10] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index underperformed the CSI 300 index by 2.13% over the past week, ranking 25th among 31 industry indices [28] - Over the past month, the pharmaceutical industry index also lagged behind the CSI 300 by 5.42%, ranking 27th [29] 2. Pharmaceutical Sector Trends and Valuation - The current PE (TTM) for the pharmaceutical industry index is 36.95, above the five-year historical average of 31.12 [52] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of biological agents and oral drugs, and the impact of policy support on the inhalation drug industry [55] 4. Important Industry Policies and News - Recent policies include the issuance of the fourth batch of encouraged generic drug directories by the National Medical Products Administration [57] - Significant news includes GSK's announcement of positive Phase III results for Bepirovirsen and Yilian Biotech's licensing agreement with Roche [58][59]

Core Viewpoint - The controlling shareholder and chairman of Junshi Biosciences, Mr. Xiong Jun, plans to increase his shareholding in the company by at least RMB 100 million over the next 12 months, with a minimum of RMB 50 million allocated for A-shares [2]. Group 1: Shareholding Details - Mr. Xiong Jun currently holds 87,856,618 shares in the company, which includes 87,854,018 A-shares and 2,600 H-shares [3]. - As of the announcement date, Mr. Xiong has cumulatively acquired 100,000 A-shares, representing approximately 0.01% of the total share capital, with a total transaction amount of RMB 3.8384 million [2]. Group 2: Progress of the Shareholding Plan - As of the announcement date, Mr. Xiong and his concerted parties collectively hold 184,083,186 shares, accounting for 17.93% of the total share capital [5]. - The shareholding increase plan is still ongoing, and Mr. Xiong intends to continue purchasing shares during the implementation period [5]. Group 3: Compliance and Regulations - The shareholding increase will comply with relevant regulations from the China Securities Regulatory Commission, Shanghai Stock Exchange, and Hong Kong Stock Exchange regarding changes in equity and sensitive trading periods [7]. - The implementation of this shareholding increase plan will not lead to changes in the company's controlling shareholder or actual controller [7].

Core Viewpoint - Junshi Biosciences (01877) announced that its controlling shareholder and chairman, Mr. Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months starting from April 12, 2025 [1] Group 1 - Mr. Xiong intends to purchase both A-shares and H-shares through the Shanghai Stock Exchange and Hong Kong Stock Exchange, with a minimum of RMB 50 million allocated for A-shares [1] - As of the announcement date, Mr. Xiong has already acquired 100,000 A-shares, representing approximately 0.01% of the company's total share capital, with a total transaction value of RMB 3.8384 million [1] - The share purchase plan is still in progress, and Mr. Xiong will continue to buy shares at opportune times during the implementation period of the plan [1]

Core Viewpoint - The chairman and controlling shareholder of Junshi Biosciences (01877), Mr. Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months starting from April 12, 2025 [1] Summary by Relevant Sections - **Shareholding Increase Plan** - Mr. Xiong intends to acquire both A-shares and H-shares of the company, with a minimum of RMB 50 million allocated for A-shares [1] - **Current Shareholding Activity** - As of the announcement date, Mr. Xiong has already purchased 100,000 A-shares through the Shanghai Stock Exchange, representing approximately 0.01% of the company's total share capital, with a total transaction value of RMB 3.8384 million [1] - **Future Actions** - The share purchase plan is still in progress, and Mr. Xiong will continue to buy shares opportunistically during the implementation period of the plan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2026年1月9日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 证券代码：688180 证券简称：君实生物 公告编号：临 2026-001 上海君实生物医药科技股份有限公司 关于控股股东、实际控制人之一兼董事长 增持股份进展公告 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證 ...

Core Viewpoint - Junshi Biosciences (688180.SH) announced that its controlling shareholder and chairman, Mr. Xiong Jun, plans to increase his holdings in the company's A-shares and H-shares by at least RMB 100 million over a 12-month period starting from April 12, 2025 [1] Group 1 - Mr. Xiong intends to invest no less than RMB 50 million in A-shares as part of this plan [1] - As of the announcement date, Mr. Xiong has already acquired 100,000 A-shares through the Shanghai Stock Exchange, representing approximately 0.01% of the company's total share capital, with a total transaction amount of RMB 3.8384 million [1] - The share acquisition plan is still in progress, and Mr. Xiong will continue to purchase shares at opportune times during the implementation period [1]